SCHEMBL3299348

SCHEMBL3299348

Cc1cc(CNCC(=O)N2CCN(C(c3ccccc3)c3ccccc3)CC2)nn1-c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA2D1 P54289 6/20 0.48
CACNA1B Q00975 6/20 0.48
CACNB1 Q02641 6/20 0.48
CACNA1C Q13936 3/20 0.48
NR2E1 Q9Y466 1/20 0.48
KMT2A Q03164 3/20 0.48
CACNA1H O95180 1/20 0.48
PKM P14618 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
MEN1 O00255 2/20 0.47
ATM Q13315 1/20 0.47
CACNA1G O43497 2/20 0.46
ALDH1A1 P00352 4/20 0.46
USP2 O75604 2/20 0.46
MAPK1 P28482 1/20 0.46
NPC1 O15118 1/20 0.45
TP53 P04637 1/20 0.44
TSHR P16473 1/20 0.44
HTT P42858 1/20 0.44
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3302027 0.86 CACNA1H (0.51) CACNA2D1CACNA1BCACNB1CACNA1CCACNA1H
SCHEMBL3302043 0.86 ALDH1A1 (0.49) KMT2ANPSR1MEN1ALDH1A1NPC1
SCHEMBL4255457 0.82 ALDH1A1 (0.39) NR2E1KMT2ACACNA1HMEN1CACNA1G
SCHEMBL3302034 0.82 ALDH1A1 (0.49) CACNA2D1CACNA1BCACNB1CACNA1CKMT2A
SCHEMBL4247744 0.81 CACNA1G (0.48) NR2E1KMT2AMEN1CACNA1GALDH1A1
SCHEMBL3295714 0.81 MEN1 (0.61) CACNA2D1CACNA1BCACNB1CACNA1CNR2E1
SCHEMBL3295658 0.79 HTT (0.50) KMT2AMEN1ALDH1A1USP2TSHR
SCHEMBL3301716 0.79 SMN1; SMN2 (0.51) KMT2ANPSR1MEN1ALDH1A1MAPK1
SCHEMBL3301621 0.77 CACNA1G (0.52) KMT2AMEN1CACNA1GALDH1A1HTT
SCHEMBL4246622 0.77 DRD3 (0.47) KMT2AMEN1CACNA1GALDH1A1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299072-B2 Pyrazolylmethylamine compounds as calcium channel modulators and preparation method thereof KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2012-10-30 US claimed
US-20100094006-A1 NOVEL PYRAZOLYLMETHYLAMINE COMPOUNDS AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2010-04-15 US claimed
US-8299072-B2 Pyrazolylmethylamine compounds as calcium channel modulators and preparation method thereof KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2012-10-30 US disclosed
US-20100094006-A1 NOVEL PYRAZOLYLMETHYLAMINE COMPOUNDS AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100094006-A1 NOVEL PYRAZOLYLMETHYLAMINE COMPOUNDS AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF CACNA1I, CACNA1C, ORAI1 CACNA2D1 44/4885CACNA1B 4/4885CACNB1 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.